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Tobacco Cessation Approaches and Impact on CVD
Harikrishnan Sivadasan Pillai, Sanjay GanapathiKerala, IndiaTobacco smoking is a major risk factor for ath-
erosclerotic vascular diseases including cardiovascu-
lar, cerebrovascular, and peripheral arterial diseases,
and aortic aneurysms. Secondhand smoke and
smokeless tobacco confers an increased risk for car-
diovascular disease (CVD).
Cessation of smoking is found to be the most
effective secondary prevention strategy in controlling
CVD, including stroke. Smoking cessation is associ-
ated with significant reduction in deaths due to
arrhythmia. It improves the lipid profile of patients.
The benefits of smoking cessation are seen in post-
coronary artery bypass graft patients and in patients
undergoing surgery for abdominal aortic aneurysms.
Smoking cessation exhibits a biphasic impact on
the cardiovascular system, with an early improve-
ment in the vasoactive properties of blood vessels
and a late response on the pathology of atheroscle-
rosis spanning several years.
Among the different tobacco cessation strategies
available, psychosocial and behavioral interventions
are primary and apparently easy to implement. Be-
cause the long-term success of these strategies is
low, most guidelines recommend adding pharmaco-
therapy to the counseling methods. Pharmacother-
apy includes nicotine replacement therapies, drugs
such as bupropion and nicotine receptor partial
agonists such as varenicline. Overall, various smok-
ing cessation strategies result in low long-term quit
rates (<30%) in patients with CVD.
However, tobacco cessation strategies are often not
given adequate importance in the clinical practice by
physicians treating patients with CVD. Further re-
search is needed to improve compliance both to behav-
ioral and pharmacotherapies to enhance quit rates.
Tobacco smoking is a major risk factor for ath-
erosclerotic vascular diseases including cardiovascu-
lar, cerebrovascular, and peripheral arterial diseasesFrom the Department of Cardiology, Sree ChitraTirunal Institute for Medic
Correspondence: H. Sivadasan Pillai (drharikrishnan@hotmail.com).and aortic aneurysms [1]. Compared with never
smokers, the risk of myocardial infarction is in-
creased 3-fold in men and 6-fold in women who
smoke more than 20 cigarettes in a day [1,2].
Smoking accounted for 36% of population-attribut-
able risk of a first myocardial infarction (MI) in the
INTERHEART (A Study of Risk Factors for First
Myocardial Infarction in 52 Countries and Over
27,000 Subjects) study [3]. In addition, involuntary
smoking (secondhand smoke [SHS]) has been
found to increase the risk of CVD by 25–30%, as
indicated in the 2006 U.S. Surgeon General’s re-
port [4].
Cessation of smoking may be as effective or
more than other secondary prevention strategies
in CVD [5]. Despite all available evidence, tobacco
cessation strategies are often not given adequate
importance in the clinical practice by physicians
treating patients with CVD.
This review discusses the impact of tobacco ces-
sation on CVD and the various approaches at the
individual level to tackle this problem. In the initial
sections, we deal with the observational evidence of
the impact of smoking cessation in primary and sec-
ondary prevention settings and in the control of
CVD risk factors. Subsequently, we deal with the
different tobacco cessation strategies available and
the impact of each modality. The last section deals
with the problems associated with each strategy and
the possible solutions. We also have included a
small section on the strategies in the pipeline on
smoking cessation at the end of this paper.
I M PAC T O F TOBACCO C E S SA T I ON ON
CVD
The positive effect of smoking cessation on primary
prevention of cardiovascular events was demon-al Sciences and Technology, Thiruvananthapuram, Kerala 695011, India.
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examined changes in cardiovascular risk factors and
incidence of MI in a cohort of 7,735 middle-aged
men observed prospectively over a period of
25 years, from 1978 to 2003. There was a 62%
reduction in the hazard of MI over this period, of
which cessation of smoking itself could account
for a 23% reduction and was the highest contribu-
tor in this regard [6].
Smoking cessation remains the single most
important secondary prevention strategy in smokers
with CVD to date. Smoking increases the risk of
all-cause mortality and cardiovascular deaths in
both male and female smokers of any type of tobac-
co, irrespective of the frequency of smoking (Ta-
ble 1) [7]. The rates of both cardiovascular
mortality and nonfatal reinfarctions are signifi-
cantly reduced in patients with CVD who discon-
tinue smoking. One of the earlier studies
observed a 50% reduction in mortality caused by
atherosclerotic disease within 5 years of cessation
of smoking in both men and women [8]. A system-
atic review of 20 studies revealed a 36% crude rel-
ative risk reduction of mortality of patients with
coronary heart diseases (CHD) who quit smoking
when compared with those who continued the
same, with most of the risk reduction realized
within 2 years of cessation [5]. In comparison, the
figures for the other secondary prevention strategies
for CHD include: statin use––29% reduction, aspi-
rin––15%, beta blockers––23%, angiotensin-con-
verting enzyme inhibitors––23% [5]. The pooled
relative risk for nonfatal reinfarction was 0.68
(95% confidence interval [CI]: 0.57–0.82) as re-
ported in this systematic review. This effect of
smoking cessation in CVD mortality has been ob-
served in both sexes as well as in all ethnicitiesTable 1. Tobacco smoking and mortality
Cause of
death
Never
smokers
Ex-smokers Quitters Light s
Cigarettes Other
type(s) of
tobacco
Cigaret
All-cause mortality
Men 22.0 25.1 30.2 40.8 33.9
Women 15.0 14.7 20.1 21.1 21.4
Cardiovascular diseases
Men 7.4 8.5 11.4 11.2 10.5
Women 4.9 3.8 5.8 2.4 5.4
Age-adjusted mortality rates (per 1,000 person-years) by smoking status, tobacco t
pooled study population (N = 19,732), Copenhagen Centre for Prospective Populat
et al. [7].[9,10]. The reduction in all-cause mortality has
been observed across all ages and is higher in those
who discontinue smoking early [11] (Fig. 1).
The effect of smoking cessation in patients with
left ventricular (LV) systolic dysfunction has been
analyzed in a few studies. Data from the SOLVD
(Studies of Left Ventricular Dysfunction) study
was available for comparison of all-cause mortality
rates between current smokers and never and ex-
smokers (stopped smoking >2 years). Never smok-
ers or ex-smokers, compared with current smokers,
had a 30% reduced risk of dying over 41 months.
Patients who had stopped smoking (>2 years) had
comparable mortality rates with never smokers.
The increased risk in smokers was accounted for
by higher event rates in patients with ischemic
LV dysfunction (n = 4,080 patients); the subgroup
with nonischemic LV dysfunction (n = 1,428 pa-
tients) did not demonstrate this difference [12].
A previous analysis of more than 350,000 subjects
screened for the MRFIT (Multiple Risk Factor
Intervention Trial), followed up for idiopathic di-
lated cardiomyopathy deaths (n = 206), revealed a
39% higher risk for same in people smoking at least
1 pack of cigarettes per day versus never smokers
and ex-smokers (p < 0.001) after adjustment for
other CVD risk factors [13].
Smoking was found to increase the risk of sud-
den cardiac death (SCD) in patients with CVD
[14], as well as in those without CVD [15]. Smok-
ers were found to have a higher risk of appropriate
implantable cardioverter-defibrillator shocks as well
[16,17]. In another study, nicotine was found to re-
sult in a catecholamine-excess state, thereby predis-
posing subjects to life-threatening arrhythmias
[18]. Smoking cessation was associated with signif-
icant reduction in deaths due to arrhythmias duringmokers Reducers Heavy smokers
tes Other
type(s) of
tobacco
Cigarettes Other
type(s) of
tobacco
Cigarettes Other
type(s) of
tobacco
32.1 42.4 41.8 39.4 42.0
22.6 32.8 32.6 28.3 31.7
10.0 13.5 13.4 11.3 11.3
2.5 6.3 0 6.3 11.1
ype, and sex, for deaths from all causes and cardiovascular diseases in the
ion Studies, Denmark, 1978–2000. Adapted, with permission, from Godtfredsen
Figure 1. Effects on survival of stopping smoking cigarettes
from ages 25–34 years (effect from age 35), ages 35–44 years
(effect from age 40), ages 45–54 years (effect from age 50),
and ages 55–64 years (effect from age 60). Reprinted with
permission, from Doll [11].
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131prospective evaluation in a high-risk cohort of pa-
tients with post-MI LV dysfunction in the CAST
(Cardiac Arrhythmia Suppression Trial) [19].
Occurrence of SCD in patients with a history of
aborted SCD was higher in smokers than in those
who quit smoking in a 4-year follow-up study [20].Patients with coronary artery disease who quit
smoking were found to have the same risk of SCD
as never smokers with coronary artery disease [14].
Patients with coronary artery disease who have
undergone revascularization have better long-term
outcomes after smoking cessation. In the North
American CASS (Coronary Artery Surgery Study)
Registry, for patients who smoked at baseline and
were randomized to bypass surgery, the 10-year
survival was better for those who quit smoking
after surgery (84%) versus 68% for those who con-
tinued to smoke (p = 0.018) [21]. Another study
conducted at the Mayo Clinic (Rochester, Minne-
sota) demonstrated that the risk of mortality (rela-
tive risk [RR] = 1.76) and that of development of
Q-wave MI (RR = 2.08) were higher in smokers
than in quitters after percutaneous coronary inter-
vention [22].
Smoking and hypertension. The effect of tobacco
smoking and its cessation on blood pressure is a
matter of debate. Smoking acutely increases blood
pressure as well as heart rate due to sympathetic
nervous system activity [23]. However, some stud-
ies reported lower blood pressure levels for habitual
smokers than for nonsmokers [24], with an inverse
relationship of blood pressure with serum levels of
cotinine (a metabolite of nicotine, which has
vasodilatory properties) [25]. In the Women’s
Health Study conducted in the United States, a co-
hort of 28,236 health professionals, who were free
of hypertension, CVD, or cancer to begin with,
were followed beginning in 1993, and it was found
that current smoking (P15 cigarettes per day) was
found to be modestly associated with development
of hypertension (age adjusted hazard ratio: 1.11,
95% CI: 1.03–1.21) when compared with never
smokers at the end of 9.8 years [26].
The effects of smoking cessation on blood pres-
sure are by and large inconclusive, with some stud-
ies reporting an increase in blood pressure [27], and
others reporting no increase [28,29] or even early
reduction in blood pressure on cessation [30–32].
Various postulates including weight gain as a result
of higher total food intake and increased stress as a
consequence of smoking cessation are provided as
reasons for the observed increase in blood pressure
after tobacco cessation. However, smoking
increases the risk of CVD and renal dysfunction
in patients with hypertension [33].
Smoking, peripheral arterial disease, and
abdominal aortic aneurysm. Smoking is an inde-
pendent risk factor for development and progres-
sion of peripheral arterial disease (PAD) and
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cohort studies. The risk, which is there for both the
sexes, may persist even after discontinuation of the
habit [34]. In another analysis from the Women’s
Health Study, after a median follow-up of
12.7 years, the age-adjusted rate of PAD was more
than 10-fold higher in smokers (>15 cigarettes per
day) than in nonsmokers, with the risk being high-
er in pre-menopausal women. Though the risk of
developing symptomatic PAD was substantially re-
duced on cessation of smoking, the risk remained
higher than for nonsmokers even if the cessation
was 20 years prior [35].
Smoking is the strongest risk factor for abdom-
inal aortic aneurysm (AAA), with the risk being
correlated stronger with the duration of smoking
than with the number of cigarettes smoked per
day [36]. The risk for AAA persists for as much
as 10 years after cessation of smoking [37]. In pa-
tients with a small AAA, smoking cessation re-
sulted in a relative risk reduction for elective
AAA repair by 9% and for rupture by 38% over
10 years of follow-up [38].
Smoking and lipid abnormalities. Heavy smokers
were observed to have higher levels of serum tri-
glycerides, lower levels of serum high-density lipo-
protein cholesterol [39,40], and higher serum levels
of oxidized low-density lipoprotein (LDL), which
promotes atherosclerosis [41]. These changes were
observed to be reversed by 1–2 months after smok-
ing cessation with the maximum reduction ob-
served for LDL cholesterol, which reduced by a
mean of 5.6% [42].
Maternal smoking and risk of congenital heart
disease. Very few epidemiological studies have as-
sessed the association of congenital heart diseases
with maternal smoking. A Swedish population-
based, case–control study showed an increased risk
of atrial septal defects in infants of mothers who
smoked (odds ratio [OR]: 1.63, 95% CI: 1.04–
2.57) versus nonsmoking mothers [43]. In the Bal-
timore–Washington Infant Study––the first popula-
tion-based case–control study of congenital heart
diseases in the United States, self-reported first-tri-
mester maternal cigarette consumption was associ-
ated with increased risk of certain types of
congenital heart defects: secundum-type atrial sep-
tal defects (OR: 1.36, 95% CI: 1.04–1.78); right
ventricular outflow tract defects (OR: 1.32, 95%
CI: 1.06–1.65); pulmonary valve stenosis (OR:
1.35, 95% CI: 1.05–1.74); truncus arteriosus (OR:
1.90, 95% CI: 1.04–3.45); and levo-transposition
of the great arteries (OR: 1.79, 95% CI: 1.04–3.10) [44]. In theNational Birth Defects Prevention
Study, maternal smoking during the month prior to
pregnancy and in the first trimester was associated
with an increased risk of septal defects [45].
Smoking and stroke. In a meta-analysis of 32 stud-
ies, the overall RR of stroke associated with ciga-
rette smoking was estimated to be 1.5 (95% CI:
1.4–1.6) with subarachnoid hemorrhage demon-
strating the highest RR of 2.9, cerebral infarction
having an RR of 1.9, and cerebral hemorrhage
being not associated (RR: 0.7) [46]. The risk of
stroke was observed to be reduced by 2 years of
abstinence in the Framingham cohort and was
found to reach the levels of never smokers by
5 years [47,48].
Smokeless tobacco and CVD. The U.S. Food and
Drug Administration has defined ‘‘smokeless to-
bacco’’ (ST) as any finely cut, ground, powdered,
or leaf tobacco that is intended to be placed in
the oral cavity. It also includes snuff. Current users
of ST have a modest, but independent risk associ-
ation with CVD mortality. The INTERHEART
Study has shown that chewing tobacco alone was
associated with an OR of 2.23 (95% CI: 1.41–
3.52), and smokers who also chewed tobacco had
the highest increase in risk (OR: 4.09, 95% CI:
2.98–5.61) [3]. A meta-analysis of 11 studies,
mainly from the United States and Sweden yielded
a RR of 1.13 (95% CI: 1.06–1.21) for fatal MI
among current users versus nontobacco users. RR
of fatal stroke was found to be 1.40 (95% CI:
1.28–1.54) [49]. Because of its sodium content
and the presence of nicotine and licorice, ST use
is associated with higher systolic and diastolic
blood pressure. A study that compared the preva-
lence of hypertension in exclusive ST users versus
nonusers in North India revealed significantly
higher estimates for diastolic hypertension in exclu-
sive ST users (40.9% versus 22.9%, p value = 0.01)
[50]. The effects of various pharmacotherapy and
behavioral therapy measures in assisting ST cessa-
tion were found to be inconclusive [51].
Smoking cessation and timeframe of
cardiovascular beneﬁts. The effects of smoking
cessation on the cardiovascular system can be con-
sidered as a biphasic response, with an early
improvement in dynamic components involving
the vasoactive properties of the blood vessels, endo-
thelial function, and vessel wall stiffness over the
initial few months, which is followed by changes
in atherosclerotic processes over the subsequent
years. These are reflected on the clinical parameters
as well as the CVD risk of the individual (Fig. 2).
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compliance were observed early after abstinence
with significant reduction in blood pressure as early
as 2 months [30] and reduction in the stiffness of
vessel wall by 6 months [31]. The cardiovascular
biomarkers including total leukocyte count, choles-
terol levels, and urinary excretion of catechola-
mines were found to be significantly reduced in
patients initiated on tobacco reduction/cessation
therapy when compared with smokers as early as
3 months into therapy [42,52]. The plasma fibrin-
ogen levels were significantly reduced in quitters
when compared with smokers by 6 months [53].
Regions with antitobacco laws have noted reduc-
tions in hospital admission rates of MI as early as
3–6 months after enforcement of the ban [54].
Most of the risk reduction for mortality occurs in
the first 1–3 years of cessation of smoking. The risk
of nonfatal CVD was found to reduce by one-half
within a year of cessation [10]. Most of the studies
found that the risk of coronary events approach the
level of nonsmokers by 3–5 years after cessation of
smoking [55–57]. Similar results were observed in
women as well [58,59]. However, many studies
have concluded that the risk of CVD for quitters
equals that for never smokers after 10 years of
abstinence [58]. The risk for PAD persisted even
20 years after cessation [35].
TOBACCO C E S SA T I ON S T RA T EG I E S
Tobacco cessation strategies can be community-/
population-oriented and those targeting the indi-
vidual. Community approaches include improvingFigure 2. Timeline of benefits on smoking cessation pertaining to C
of smoking by 40 years of age. See text. BP, blood pressure; CVD, c
vascular disease.the awareness of the ill effects of smoking through
campaigns and advertisements and including it in
the educational curriculum of schools and colleges.
Imposing a smoking ban in public spaces and
increasing taxation for tobacco, banning tobacco
advertisements, and inserting warning signs in to-
bacco products are other population-based
strategies.
Approaches targeted at the individual include
self-help, counseling, single pharmaceutical agents,
combined pharmacotherapies, and pharmacothera-
pies combined with psychological counseling
[1,60–62].I M PAC T O F VAR I OU S TOBACCO
C E S SA T I ON S T RA T EG I E S ON CVD
Tobacco use results in tolerance and physical
dependence, so withdrawal symptoms occur when
the habit is discontinued. So interventions targeted
at smoking cessation address both the physiological
and psychological aspects of nicotine dependence.
Analyses have documented the efficacy of both
psychological counseling and pharmacotherapy in
this regard [1].
Psychosocial interventions including behavioral
therapy, telephone support, and self-help methods
have been found to increase the quit rates, with
more intense and sustained methods showing bet-
ter results. Quitlines are telephone-based tobacco
cessation services that help smokers quit through
a variety of services, including counseling, provid-
ing information about treatment modalities, andVD risk. The curve indicates 20-year survival for men on cessation
ardiovascular disease; MI, myocardial infarction; PVD, peripheral
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to the individual tobacco user based on the user’s
experience, tobacco use behavior, and motivations.
Such measures were found to be most effective
when initiated after an episode of acute coronary
syndrome in the hospital by a trained nurse [61].
However, such methods were not found to be
much effective over a longer period of time. A
meta-analysis of 16 randomized clinical trials (con-
ducted in Europe, the United States, Canada, and
Australia), each with a minimum follow-up of
6 months noted that brief interventions in CHD
patients with no follow-up contact within 1 month
had dismal quit rates at 6–12 months (OR: 0.92,
95% CI: 0.70–1.22). Whereas the quit rates im-
proved with follow-up contacts after 1 month
(OR: 1.98, 95% CI: 1.49–2.65), and it was esti-
mated that about 10 CHD patients had to be trea-
ted with sustained interventions for 1 patient to
remain abstinent from tobacco at the end of 1 year
[60]. Hence, the guidelines for smoking cessation
recommend the addition of pharmacotherapy to
the counseling methods [61].
Pharmacotherapy. Nicotine replacement therapy
(NRT) delivers a steady dose of nicotine to the sys-
tem by alternate routes (noninhalational). All
modes of NRT––transdermal patch, gum, inhaler,
lozenges, and nasal spray––were found to be almost
similarly effective, increasing the quit rates to
nearly 2-fold over placebo [62]. Several studies
have evaluated the safety of NRT use in patients
with CVD, especially transdermal nicotine patch
in both clinical and population-based settings.
There was no increase in the event rate of MI
and other endpoints in the active treatment group
(transdermal patch) versus the placebo group
[63]. A population-based case–control study (case
subjects––smokers with first MI, control sub-
jects––smokers without MI) observed no associa-
tion between nicotine transdermal patch use and
the risk of MI [64].
Studies assessing the direct impact of NRT on
CVD risk reduction are not available and are rather
impractical due to the need for large numbers and
long follow-up. One study assessing the efficacy
of high-dose nicotine patches reported a less-
than-expected MI rate (expected MI rate was cal-
culated from the data of Framingham study) over
the study period of 1 year [65]. The acute effects
of transdermal nicotine patch (increase in heart
rate, increase in mean arterial pressure) are not ob-
served in habituated smokers who are tolerant to
vasoactive properties of lower doses of nicotine[63]. However, the smoking cessation guidelines
recommend caution on the use of NRT in patients
with an acute coronary event in the past 2 weeks or
in those with a history of serious arrhythmias [1].
Bupropion is an antidepressant agent and is rec-
ommended by the guidelines as a first-line therapy
for smoking cessation [61]. Systematic reviews have
observed that bupropion is almost twice as effective
as placebo for smoking cessation [66]. Bupropion
with the nicotine patch doubled the rate of absti-
nence from smoking at the end of 1 year when
compared with the nicotine patch alone in another
study [67]. Bupropion is safe for use in smokers
with stable CVD and was not found to result in ad-
verse cardiac events in such patients [68]. However,
bupropion appears to be less effective for smoking
cessation when initiated in the setting of hospital-
ization for acute coronary events. The 12-week
smoking abstinence rate with bupropion was not
significantly different from that with placebo, but
there was a nonsignificant higher adverse cardio-
vascular event rate in the bupropion group [69].
Nicotine receptor partial agonists such as varen-
icline or cytisine are also found to be effective in
smoking cessation strategies. Compared with pla-
cebo, varenicline demonstrated superiority in
smoking cessation (duration of therapy: 6 months,
pooled risk ratio = 2.3) and to bupropion (duration
of therapy: 12 months, pooled risk ratio = 1.52)
with reported 6-month abstinence rates up to
33% [70]. However, there are concerns regarding
the risk of adverse cardiovascular events in smokers
using varenicline [71]. But a recent meta-analysis
published in May 2012 that included 22 trials pub-
lished to date, focused on events occurring during
drug exposure, and analyzed findings using 4 sum-
mary estimates found no significant increase in car-
diovascular serious adverse events associated with
varenicline use [72].
Overall, various smoking cessation strategies
targeting the individual smoker (behavioral and
pharmacotherapy) result in low long-term quit
rates (<30%) in patients with CVD [68], implying
the need for combining the individual-based ap-
proaches with community-based strategies.
Effects of limiting SHS exposure. Unlike the case
with lung cancer, SHS has a nonlinear dose response
relationship with CVD, with excess risk even at low-
er doses [73]. Nonsmokers exposed to SHS were
found to have blood markers suggesting inflamma-
tory activity including total leukocyte count, raised
C-reactive protein, fibrinogen, homocysteine, and
oxidized LDL cholesterol levels, similar to the levels
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135observed in active smokers [74,75]. In a study
assessing the acute effects of passive smoking,
SHS exposure of 30-min duration provoked coro-
nary vasoreactivity, the magnitude of which was
higher in nonsmokers than in smokers [76]. Anginal
thresholds are reduced on exposure to SHS.
The first results of a community-level smoking
ban in Helena, Montana, USA, observed as much
as a 40% reduction in hospital admission of pa-
tients with MI for the 6-month period during
which the ban was in force when compared with
the previous 6-month period. Once the ban was
lifted, the hospital admission rates of patients with
MI returned to baseline levels after 6 months [77].
In a meta-analysis of 11 studies in 10 locations,
community smoking bans were found to be associ-
ated with an overall 17% risk reduction of MI [78].
The benefit of a smoking ban on MI rates was ob-
served within as early as 3 months after the ban be-
gan [54]. The effects of smoking laws were found
to accumulate over time as evidenced by a 15% risk
reduction in MI rates at the end of the first year of
a smoking ban to 36% by the end of a 3-year per-
iod [79].
Impact of smoking reduction. Reduction in the
number of cigarettes smoked per day may result in
clinically inconsequential improvement in blood
parameters such as fibrinogen, leukocyte count,
and blood cholesterol. However, these are not
translated to improved CVD outcomes [7,68]. A
prospective cohort study assessed the effect of
smoking cessation and smoking reduction on the
risk of MI and observed that whereas smoking ces-
sation was beneficial, smoking reduction by as much
as 50% failed to result in any clinical benefit [80].
Barriers to smoking cessation strategies. Smoking
cessation approaches in developing countries are
not organized. Even though population-oriented
approaches, such as increasing taxation, ban of
smoking in public places, banning adverts, are
implemented with significant success, strategies
targeted at the individual smoker have not been
well evaluated to demonstrate success. For exam-
ple, in India, there are only a few tobacco cessation
clinics, and they are in tertiary care centers, which
are inaccessible to the vast majority. Another
problem is that in India, the tobacco cessation clin-
ics are usually attached to a psychiatry department,
hence the taboo and less acceptance. Patients often
hesitate to attend psychiatry clinics due to the
taboo of being labeled as a person having a psychi-
atric illness by societal peers. Hence, such services
may not be received well by those who need it. Itis sad that most of the academic or corporate hos-
pitals in the developing world lack dedicated anti-
tobacco clinics. There are hardly any self-help
groups, and there are not many counselors.
One important reason for this phenomenon is
that tobacco cessation strategies are not given
adequate importance in the medical/nursing/para-
medical curriculum. Lack of funds, lack of infra-
structure, and physicians overburdened with
clinical work add to the problem. Even though
the patient will be most receptive (to advice regard-
ing smoking cessation) following an admission for
an acute coronary syndrome (‘‘teachable moment’’),
the percentage of patients receiving advice regard-
ing smoking cessation is very low [81,82]. It is
found that a brief advice of 30 seconds by physi-
cians produce quit rates of 5–10% per year [83].
But it is reported in a recent meta-analysis that
offering assistance by physicians to quit smoking
generated more quit attempts than those by pro-
viding advice alone [84].
Lack of training programs and the absence of
successful models (smoking clinic) suitable for the
developing world are other issues. Poverty and lack
of awareness complicate these factors, impeding
the success of such initiatives. The expense of phar-
macotherapy is yet another factor. Nicotine patch
and pharmacotherapy are often not affordable in
a developing country setting: for example, a 28-
tablet package of varenicline (1-mg strength) costs
about INR 1,628 (approximately US$82) in India.
In a qualitative study from Australia, the clients
from disadvantaged sections desired to have finan-
cial incentives and access to free or subsidized NRT
as part of a smoking cessation strategy [85]. But
there are no studies comparing subsidized pharma-
cotherapy with other strategies.
Possible solutions. Because the lack of dedicated
smoking treatment clinics is the crux of the issue,
the priority should be to establish a few pilot cen-
ters in each country. Initially we have to test and
modify such a facility to suit the local environment
and then establish more of them.
The other key issue is the lack of follow-up of
these patients. Because the penetration of mobile
phones in most of the developing world is high,
they can be used as an effective way for follow-up.
Including smoking cessation strategies in the
medical curriculum is another strategy that can
improve the situation. Physician associations in
each country should realize the importance of the
issue and should direct their members to adopt
smoking cessation strategies.
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logical agents that can reduce the dependence on
nicotine is one option. Some of the drugs being
tested include the newer generation neuronal nico-
tinic acetylcholine receptor partial agonists, can-
nabinoid receptor 1 antagonists, dopamine D3
antagonists, and monoamine oxidase inhibitors.
Nicotine vaccine is another modality that is
being tested. Nicotine, being a small molecule, is
rendered immunogenic by linking with a carrier
protein, resulting in production of antibodies that
bind to nicotine released into the bloodstream dur-
ing smoking. This prevents nicotine from crossing
the blood–brain barrier. With reduced amounts of
nicotine reaching the brain, fewer stimulants are
released and the pleasurable, positive-reinforcing
effects of nicotine are diminished, thereby making
it easier to quit smoking. NicVAX, the vaccine
developed by GlaxoSmithKline (Brentford, United
Kingdom) is in phase 3 development. The other
nicotine-derived therapeutic vaccines are Nic-002,
TA-Nic, and Niccine, being developed by Cytos
Biotechnology/Novartis Pharmaceuticals (Zurich,
Switzerland/Basel, Switzerland), Celtic Pharma
(New York, New York, USA), and Independent
Pharmaceutica (Stockholm, Sweden), respectively
[86].
Strategies based on genomics can be used in to-
bacco cessation. Genetic testing has been proposed
as a means to increase smoking cessation rates and
thus improve smoking reduction approaches. Phar-macogenetics can be used to determine the poten-
tial effectiveness of antitobacco drugs. But it is felt
that although genetics offers increasing opportuni-
ties to tailor drug treatment, and may in some cases
provide useful risk prediction, other methods of
personalizing care are likely to yield greater benefit
to populations experiencing health disparities re-
lated to tobacco use [87].CONC LU S I ON S
Tobacco smoking is a major risk factor for athero-
sclerotic vascular diseases and smoking cessation
remains the single most important secondary pre-
vention strategy. Among the different tobacco ces-
sation strategies available, psychosocial
interventions coupled with pharmacological mea-
sures may result in good short-term results, but
the overall long-term adherence is dismal. Many
factors contribute to the failure of these strategies
especially in the developing world where CVD is
rampant. The benefits of avoidance of tobacco
and cessation of tobacco use calls for global escala-
tion of the antitobacco drive. Increasing the aware-
ness about tobacco cessation strategies among the
physician and paramedical community and estab-
lishment of tobacco cessation clinics will be helpful
to some extent. It would be worthwhile to empha-
size that mere reduction in the degree of smoking
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